Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, LTD. (KAPA) on September 18, 2025. The filing reports a significant corporate event under Item 8.01 (Other Events) regarding the company's clinical development program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements or quantitative financial data.
Material Changes and Events
- Clinical Trial Update: The Company announced positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab).
- Indication: The trial involves patients with metastatic castration-resistant prostate cancer (mCRPC).
- Stakeholder Engagement: A virtual Key Opinion Leader (KOL) event was held on September 18, 2025, at 5 p.m. ET to discuss the data.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 8.01 and the accompanying exhibits (Press Release and Slide Presentation) is "furnished" and not "filed" under the Securities Exchange Act of 1934. Consequently, this information is not subject to liabilities under Section 18 of the Exchange Act and is not incorporated by reference into other Company filings. The filing explicitly states it is not an admission as to the materiality of the information contained therein.
Investor Verification Checklist
- Review the full text of the Press Release (Exhibit 99.1) for specific efficacy data points and statistical significance.
- Examine the Slide Presentation (Exhibit 99.2) for detailed trial design, patient demographics, and safety profiles.
- Verify the status of the Phase 2 trial and any subsequent regulatory milestones or next steps outlined in the KOL event.
- Check subsequent filings for any updates on the commercialization strategy or partnership discussions related to ENV105.